Kyntra Bio Receives Nasdaq Delisting Notice
Nasdaq has notified Kyntra Bio that its common stock will be delisted from the Nasdaq Global Select Market due to non-compliance with listing rules by the September 29 deadline. The company has requested a hearing, which temporarily stays the suspension.